首页 | 本学科首页   官方微博 | 高级检索  
     


Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast‐phase myeloproliferative neoplasms
Authors:Raynier Devillier  Emmanuel Raffoux  Jérôme Rey  Etienne Lengline  Anne‐Marie Ronchetti  Marie Sebert  Nicolas Boissel  Marie Robin  Norbert Vey  Jean‐Jacques Kiladjian  Herve Dombret  Thomas Cluzeau
Affiliation:1. Haematology Department, Institut Paoli Calmettes, Marseille, France;2. Aix‐Marseille University, Marseille, France;3. Adult Haematology Department, Saint Louis Hospital, Paris, France;4. Senior Haematology Department, Saint Louis Hospital, Paris, France;5. Adolescents and Young Adults Haematology Department, Saint Louis Hospital, Paris, France;6. EA3518, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France;7. Allo Stem Cell Transplantation Department, Saint Louis Hospital, Paris, France;8. Centre d'Investigation Clinique (CIC), Saint Louis Hospital, Paris, France;9. INSERM U1065, Centre mediterraneen de Medecine Moleculaire, Nice, France
Abstract:
Keywords:ruxolitinib  myeloproliferative neoplasm  blast phase  acute myeloid leukaemia  intensive chemotherapy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号